

PHOSPHOLIPASE A₂ MODULATION BY CALMODULIN,
PROSTAGLANDINS AND CYCLIC NUCLEOTIDESNathan Moskowitz, Lawrence Shapiro,¹
William Schook, and Saul Puszkin²Laboratory of Molecular Pathology, Department of Pathology
Mount Sinai School of Medicine of the City University of New York
New York, New York 10029

Received July 12, 1983

Phospholipase A₂ in the presence of Ca²⁺ was stimulated by calmodulin and by prostaglandin F_{2α}. Prostaglandin E₂, cyclic-AMP and cyclic-GMP inhibited phospholipase A₂ in the presence or absence of calmodulin. Dimethylsuberimide cross-linking of phospholipase A₂ with calmodulin was found to be Ca²⁺ dependent. These results indicate that phospholipase A₂ is directly regulated by a host of key intracellular regulators and is one of the calmodulin-regulated enzymes.

Phospholipase A₂ (PLA₂), which catalyzes the fatty ester hydrolysis of 1,2 sn-phosphoglycerides in the 2-position, is a Ca²⁺-dependent enzyme ubiquitously distributed in eukaryotic and prokaryotic membranes (1). Membrane PLA₂ functions in lipid metabolism, prostaglandin (PG) production, membrane fusion, chemotaxis, neurotransmitter release and coated vesicle endocytosis (2-7). Calmodulin is an ubiquitous cellular Ca²⁺-binding protein which activates a host of enzymes (8). Prostaglandins are oxygenated and unsaturated carbon fatty acids containing a cyclopentane ring performing many diverse cellular functions (9). We previously reported that PLA₂ activity was present in synaptic vesicles and was stimulated by calmodulin (CaM) and PGF_{2α} and inhibited by PGE₂ (6). To ascertain whether CaM, PGF_{2α} and PGE₂ had direct effects on PLA₂, we studied a highly purified PLA₂ which has an amino acid sequence homologous to mammalian PLA₂.

¹ Present address: Department of Biophysiology, California Institute of Technology, Pasadena, CA 91125

² To whom correspondence should be addressed.

(10). Because the actions of PGE_2 and $\text{PGF}_{2\alpha}$ may be mediated via interaction with adenylate and guanylate cyclases which generate cAMP and cGMP respectively (11), we tested the effects of cAMP and cGMP on this enzyme.

MATERIALS AND METHODS

Reaction mixtures containing 1 pgm PLA₂ purified from *Naja naja* snake venom (Sigma, St. Louis, Missouri), 1 mM CaCl_2 and 1.8 nmol [^{14}C]- β -arachidonylphosphatidylcholine (S.A. 54 mCi/mmol, Amersham, Arlington Heights, Illinois) were incubated for 10 minutes at pH 8.9 at 25°C under the following two conditions: 1) with increasing concentrations of CaM (10^{-9} - 10^{-3} M), PGE_2 , $\text{PGF}_{2\alpha}$, cAMP or cGMP (10^{-9} - 10^{-3} M), or 2) with CaM (10^{-7} M) and increasing concentrations of PGE_2 , $\text{PGF}_{2\alpha}$, cAMP or cGMP (10^{-9} - 10^{-3} M). Reactions were stopped, processed and PLA₂ activity assayed as described previously (6, 13). Phospholipase cross-linking was performed using dimethylsuberimidate (DMS [Aldrich, Milwaukee, Wisconsin]), an alkylimidate ester which joins proteins that form a complex within 11 Å from each other under a variety of conditions (14). Phospholipase A₂ (20 µg) was incubated in a total volume of 60 µl with 0.42 µg/ml DMS dissolved in 20 µM triethanolamine buffer, pH 8.5, for 30 minutes in the absence or presence of either PGE_2 (10^{-5} M), $\text{PGF}_{2\alpha}$ (10^{-5} M), cAMP (10^{-3} M) or cGMP (10^{-3} M). For each of these four conditions there were the following subconditions: incubation in the presence of 1) 1 mM CaCl_2 ; 2) 1 mM EGTA; 3) 1 mM CaCl_2 and 7 µg CaM; or 4) 1 mM EGTA and 7 µg CaM. The reactions were stopped with 14 µl phenol red solution containing 1 mM β -mercaptoethanol and 10% sodium-dodecyl-sulfate (SDS). Protein was measured as described by Lowry *et al.* (15) and protein composition was analyzed by 5-15% SDS polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie blue (16)

RESULTS AND DISCUSSION

Calmodulin induced a dose-dependent stimulation of PLA₂ activity reaching maximum stimulation at 1.0×10^{-6} M (Fig. 1.).




Fig. 1. *Naja naja* PLA₂ activity plotted as a function of CaM concentration. PLA₂ was incubated with CaCl_2 (1 µmole) and 1.85 nmol [^{14}C]-arachidonylphosphatidylcholine and incubated for 10 minutes at 25°C in 100 mM Tris-HCl buffer, pH 8.9.




Fig. 2. A: PLA₂ was incubated with CaCl₂ (1 μmole) and 1.85 nmol [¹⁴C]-arachidonylphosphatidylcholine and incubated for 10 minutes at 25°C in 100 mM Tris-HCl buffer, pH 8.0. PLA₂ activity is plotted as a function of PGE₂ (▲) or PGF_{2α} (●) in the presence of CaCl₂ or CaCl₂ and 1 μM CaM (X) and (■) respectively. The origin of the curves represents the baseline values of enzymatic activity in the presence or absence of CaM, viz., 11.0 pmol of a.a./pgm/min in the absence of CaM and 17.0 pmol of a.a./pgm/min in the presence of CaM; B & C: PLA₂ activity plotted as a function of cAMP or cGMP concentrations in the absence (●) or presence (■) of CaM. The origin of the curves represents the baseline values of enzymatic activity in the presence or absence of CaM shown in Fig. 1.

In the absence or presence of CaM, PGF_{2α} stimulated PLA₂ in a dose-dependent manner achieving maximum activation of 63.6% and 106% increases in enzymatic activity respectively (Fig. 2a). Prostaglandin E₂ in the absence or presence of CaM induced 50% and 35% inhibitions of PLA₂ at 1 nM and 10 μM, respectively (Fig. 2a). Thus PGF_{2α} and PGE₂ had opposite effects on PLA₂ in the presence and absence of CaM. Cyclic-AMP and cGMP inhibited PLA₂ activity in the presence or absence of CaM (Figs. 2b and 2c). Upon DMS cross-linking in the presence of Ca²⁺, polypeptides of M_r 14K and 21K were observed (Fig. 3a). They constituted 77% and 23% of the total protein, respectively. When DMS cross-linking was performed with Ca²⁺ in the presence of cAMP, cGMP or PGE₂, the number of polypeptides remained essentially unchanged (data not shown). Cross-linking using DMS in the presence of PGF_{2α} and Ca²⁺ showed new polypeptides with M_rs 24K, 28K, 31K and 33K corresponding to polymers of PLA₂ (Figs. 3b). In the presence of PGF_{2α} and 1 mM EGTA, cross-linked polymers were not present (Fig. 3b) indicating the Ca²⁺ dependence of PGF_{2α}-induced polymeriza-




Fig. 3. SDS-PAGE 5-15% gel analysis and Coomassie blue staining. A: polypeptide composition of PLA₂ with DMS cross-linker in the presence of Ca²⁺ (Lane 1), 1 mM EGTA (Lane 2), 1 mM Ca²⁺ and 7 μ g CaM (Lane 3), or 1 mM EGTA and 7 μ g CaM (Lane 4); B: polypeptide composition of PLA₂ cross-linked with DMS in the presence of Ca²⁺ and 10 μ g PGF_{2 α} (Lane 1) or 1 mM EGTA and 10 μ g PGF_{2 α} (Lane 2). C: Larger magnification showing details of bands of gel B.

tion. Prostaglandin E₂, cAMP or cGMP did not alter the extent of PLA₂ polymerization (data not shown). Upon DMS cross-linking in the presence of Ca²⁺ and CaM, additional cross-linked polypeptides were observed (Fig. 3a). The 14K and 21K polypeptides corresponded to those observed with cross-linker and Ca²⁺ alone. The new PLA₂-CaM complex appeared as a 30K polypeptide (Fig. 3a). The presence of CaM-CaM polymers was not suspected since CaM does not cross link with itself (17).

Cross-linking of PLA₂ with DMS in the presence of PGF_{2 α} , PGE₂, cAMP or cGMP in the presence of Ca²⁺ and CaM did not reveal any significant changes in the level of PLA₂-CaM complex formation (data not shown). The inhibitory effects of cAMP, cGMP and PGE₂ in the presence of Ca²⁺ alone or Ca²⁺ and CaM may be due to the direct interaction of these modulators with monomers or polymers of PLA₂. The induced conformational changes may be such that substrate/enzyme interactions are impaired or, alternatively, these modulators may inhibit substrate binding to the enzyme and thereby inhibit substrate hydrolysis.

Classically, both cAMP and cGMP have been demonstrated to exert metabolic effects only via stimulation of protein kinases (18); in this communication, PLA₂ is the only other enzyme reported to be directly controlled by cAMP and cGMP. Both CaM and cAMP, two key cellular regulators, may regulate PLA₂. Calcium/CaM activates this enzyme, whereas cAMP directly inhibits the enzyme in the presence of Ca²⁺ or Ca²⁺/CaM. Thus PLA₂ is a common focal point for both CaM and cyclic nucleotides having opposite effects. Prostaglandin E₂ and PGF_{2α}, in addition to regulating adenylate and guanylate cyclases, respectively (11), also may exert antagonistic effects by the inhibition and stimulation of a common enzyme, PLA₂.

Calcium has been hypothesized to activate PLA₂ by binding to the enzyme thus inducing conformational changes and by facilitating nucleophile deprotonation (19, 20). Membrane PLA₂ is stimulated by CaM and hormones (21, 22) and inhibited by anesthetics, antibiotics, and lipomodulin (19, 20, 23-25). Our findings, that PLA₂ can be directly regulated by the modulators herein described, imply that PLA₂ is an important enzyme with a finely regulated mechanism.

ACKNOWLEDGMENTS

This work was supported in part by N.I.H. grants #NS12467 and #HL27928 to S.P. The authors thank Elaine Hua for experimental assistance and John Morgan for editing and preparing our manuscript.

REFERENCES

1. Van den Bosh, M. (1974) *Ann. Rev. Biochem.* 43, 243-277.
2. Mosoro, E.J. (1977) *Ann. Rev. Physiol.* 39, 301-329.
3. Flowers, R.J. and Blackwell, G.J. (1976) *Biochem. Pharmacol.* 25, 285-291.
4. Heilbrunn, E. in *Psychopharmacology, Sexual Disorders and Drug Abuse*, T.A. Ban, Ed., pp. 551-554, North Holland Publ. Co., Amsterdam, 1973.
5. Hirata, F., Corcoran, B.A., Venkatasubramanian, K., Schiffmann, E. and Axelrod, J. (1979) *Proc. Natl. Acad. Sci. USA* 76, 2640-2643.
6. Moskowitz, N., Schook, W. and Puszkin, S. (1982) *Science*, 216, 305-307.
7. Moskowitz, N., Schook, W. and Puszkin, S. (1982) *J. Cell Biol.* 85, 442a.

8. Cheung, W.Y. (1980) *Science* 207, 19-27.
9. Samuelsson, B., Granstrom, E., Green, K., Hamberg, M. and Hammarstrom, S. (1975) *Ann. Rev. Biochem.* 44, 669-695.
10. Yang, C.C. and King, K. (1980) *Toxicon* 18, 543-547.
11. O'Dea, R.B. and Haddox, M.K. (1973) *Adv. Cyclic Nucleotide Res.* 3, 155-223.
12. Jamieson, Jr., G.A. and Vanaman, T.C. (1979) *Biochem. Biophys. Comm.* 90 1048-1051.
13. LaGarde, M., Menashi, S. and Crawford, N. (1981) *FEBS Lett.* 124, 23-26.
14. Peters, K. and Richards, F.M. (1977) *Ann. Rev. Biochem.* 46, 523-551.
15. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) *J. Biol. Chem.* 193 265-275.
16. Laemmli, U.K. (1970) *Nature* 227, 680-685.
17. Lisanti, M.P., Shapiro, L.S., Moskowitz, N., Hua, E.L., Puzskin, S. and Schook, W. (1982) *Eur. J. Biochem* 125, 617-622.
18. Greengard, P. (1978) *Science* 199, 146-152.
19. Volwerk, J.J., Pieterse, W.A. and deHaas, G.H. (1974) *Biochemistry* 13, 1446-1454.
20. Wells, M.A. (1973) *Biochemistry* 12, 1086-1093.
21. Haye, B., Champion, S. and Jacquemin, C. (1973) *FEBS Lett.* 30, 253-255.
22. Wong, P.Y.K. and Cheung, W.Y. (1979) *Biochem. Biophys. Res. Comm.* 90, 473-480.
23. Scherphof, G.L., Scarpa, A. and Toorenbergen, A.V. (1972) *Biochim. Biophys. Acta* 270, 226-240.
24. Sugatini, J., Saiton, K., and Honjo, I. (1979) *Antibiot. (Tokyo)* 32, 734-739.
25. Hirata, F., Schiffmann, E., Venkatasubramanian, K., Salomon, D. and Axelrod, J. (1980) *Proc. Natl. Acad. Sci. USA* 77, 2533-2536.